Global /United States /Healthcare /Biotechnology /TXG
chevron_leftBack
10x Genomics, Inc. logo

10x Genomics, Inc.

TXG
NASDAQ: TXG Delayed
20.20USD -5.5%
As of 8 June 2026, 10x Genomics, Inc. has a market cap of $2.58B USD, ranking #6008 globally and #1544 in the United States. It ranks #476 in the Healthcare sector, and #84 in the Biotechnology industry.
Global Rank
6008
Country Rank
1544
Sector Rank
476
Industry Rank
84
Key Stats
Market Cap
$2.58BUSD
Enterprise Value
$2.11BUSD
Revenue (TTM)
$642.82MUSD
EBITDA (TTM)
-$64.09MUSD
Net Income (TTM)
-$43.54MUSD
EBITDA Margin
-10%
Profit Margin
-6.8%
PS Ratio
4.0
PB Ratio
3.4
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Biotechnology
CEO
Serge Saxonov open_in_new
Employees
1,178
Founded
2012
IPO
12 Sep 2019
Website
10xgenomics.com open_in_new
warningChart data may be delayed
1d 1w 1m 3m 6m 1y
-5.5% -12% 3.7% -4.2% 51% 138%

News

Loading...

TXG Analyst Forecasts

Loading...

Markets

Exchange Ticker Price
NASDAQ
MIC: XNAS
PRIMARY
TXG
10x Genomics Inc Ordinary Shares - Class A
ISIN: US88025U1097
Shares Out.:
116.877M1 Shares Float: 112.787M2
TV:
SA:
YF:
TXG
GF:
NQ:
TXG
BA:
TXG
MS:
20.20 USD
London Stock Exchange
MIC: XLON
0A88
10x Genomics Inc Ordinary Shares - Class A
ISIN: US88025U1097
TV:
SA:
YF:
GF:
BA:
MS:
21.52 USD
Frankfurt Stock Exchange
MIC: XFRA
1KJ
10x Genomics Inc Ordinary Shares - Class A
ISIN: US88025U1097
TV:
SA:
YF:
GF:
BA:
1KJ
MS:
18.50 EUR
Show all 4 markets
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.

About 10x Genomics, Inc.

10x Genomics, Inc. develops and sells instruments, consumables, and software for analyzing biological systems in the United States, rest of the Americas, Europe, the Middle East, Africa, China, and the rest of the Asia Pacific. The company offers Chromium platform, a single cell portfolio that enables analysis of individual biological components, as well as includes microfluidic chips and related consumables, Chromium X Series, and Chromium instruments; and QuantumScale single cell RNA and single cell methylation kits. It also provides Visium platform, a spatial analysis platform that uses high density DNA arrays to encode the physical location of biological analytes within a sample. This platform includes HD WT panel gene expression, and HD 3’ gene expression assays, as well as the Visium CytAssist, an instrument designed to simplify and optimize the Visium solution workflow by facilitating the transfer of transcriptomic analytes from standard glass slides to Visium slides. In addition, the company offers Xenium Analyzer instrument enables researchers to detect and preserve the cellular location of hundreds of RNA targets directly in a fresh frozen or FFPE tissue section without the need for conventional sequencing; and slides and reagents. Further, it provides various software products comprising Cell Ranger, a scRNA-seq processing pipeline in scientific literature; Loupe Browser, which enables intuitive single-cell, spatial, and multiomic data visualization; and Xenium Explorer that enables intuitive in situ data visualization, which allows researchers to explore subcellular gene expression, spatial organization, and tissue-scale patterns. The company serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.

Similar Companies

Industry: Biotechnology (United States)
Name
Market Cap diff.
PE
AMGN
$182.42B
7K%
23.9
GILD
$159.92B
6K%
19.0
NTRA
$27.6B
970%
-
$26.3B
919%
20.0
$25.03B
870%
20.4
MRNA
$18.13B
603%
-
Industry: Biotechnology (Global)
Name
Market Cap diff.
PE
ARGX
$48.08B
41.39B EUR
2K%
39.9
$44.48B
68.19T KRW
2K%
35.5
LONN
$42.72B
33.71B CHF
2K%
37.2
CSL
$42.5B
60.27B AUD
2K%
29.3
068270
$27.89B
42.76T KRW
981%
43.8
BNTX
$25.69B
895%
-
chevron_leftBack